Ikena Oncology Ikena Oncology
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Leadership
    • Partners
    • Investors
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • IK-007 EP4 Antagonist
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
  • Careers
    • Culture
    • Job Opportunities
  • Newsroom
    • Press Releases
    • Media Kit
Select Page
    • About
      • Our Company
      • Leadership
      • Partners
      • Investors
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • IK-007 EP4 Antagonist
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
    • Careers
      • Culture
      • Job Opportunities
    • Newsroom
      • Press Releases
      • Media Kit
    • Contact
    • Privacy Policy
    • Terms of Use
    • Linked
    • Twitter

Press releases

Keep up with the latest news from Ikena Oncology.

May 7, 2019

Kyn Therapeutics Strengthens Leadership Team with Key Appointments

February 4, 2019

Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018

Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018

Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017

Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

<<12

Access our media kit page to view and download assorted corporate assets.

View Media Kit
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • Privacy Policy
  • Terms of Use
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Investors
  • Contact
  • Focus
  • Ikena™ Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • IK-007 EP4 Antagonist
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • Careers
  • Culture
  • Job Opportunities
  • Newsroom
  • Press Releases
  • Media Kit
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter
© 2021 Ikena Oncology™